A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
Latest Information Update: 08 Oct 2021
At a glance
- Drugs BMX-010 (Primary)
- Indications Atopic dermatitis; Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMimetix
- 04 Oct 2021 Status changed from active, no longer recruiting to completed.
- 13 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2022.
- 13 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.